Dublin-based Icon, a provider of outsourced drug and device development and commercialisation services continues to expand. It is to acquire Nasdaq-listed PRA Health Sciences in a US$12bn deal. “The combined company will create a new paradigm for accelerating clinical research and bringing new medicines and devices to market. Both Icon and PRA have track records…